BioNTech SE (NASDAQ:BNTX) Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp decreased its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 21.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 94,685 shares of the company's stock after selling 25,216 shares during the quarter. Van ECK Associates Corp's holdings in BioNTech were worth $10,509,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the business. Candriam S.C.A. increased its position in shares of BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock valued at $46,526,000 after buying an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. increased its position in BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock worth $37,103,000 after purchasing an additional 341,311 shares in the last quarter. New York State Common Retirement Fund increased its position in BioNTech by 457.9% during the 3rd quarter. New York State Common Retirement Fund now owns 218,067 shares of the company's stock worth $25,900,000 after purchasing an additional 178,981 shares in the last quarter. abrdn plc increased its position in BioNTech by 334.4% during the 3rd quarter. abrdn plc now owns 225,992 shares of the company's stock worth $26,841,000 after purchasing an additional 173,969 shares in the last quarter. Finally, Lodestone Wealth Management LLC purchased a new stake in BioNTech during the 3rd quarter worth about $8,373,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Stock Performance

BNTX traded up $1.70 during trading on Thursday, reaching $108.34. 309,581 shares of the company were exchanged, compared to its average volume of 781,919. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. The stock has a market cap of $25.76 billion, a P/E ratio of -50.78 and a beta of 0.26. The firm has a 50 day moving average of $111.00 and a 200 day moving average of $96.31.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company's quarterly revenue was up 38.9% compared to the same quarter last year. During the same period last year, the company earned $0.73 earnings per share. On average, sell-side analysts forecast that BioNTech SE will post -2.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BNTX has been the subject of a number of recent research reports. TD Cowen dropped their price objective on BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research report on Tuesday. UBS Group raised their price target on BioNTech from $97.00 to $131.00 and gave the stock a "neutral" rating in a research note on Wednesday, September 18th. Hsbc Global Res raised BioNTech from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 2nd. Morgan Stanley raised BioNTech from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. Finally, JPMorgan Chase & Co. decreased their price target on BioNTech from $125.00 to $124.00 and set a "neutral" rating on the stock in a research note on Monday. Five analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $134.69.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.